GEPOTIDACIN FOR USE IN THE TREATMENT OF BACTERIAL URINARY TRACT INFECTIONS
Disclosed are methods and compounds for use for treating urinary tract infection comprising administering gepotidacin or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount in a human in need thereof, wherein the urinary tract infection is caused by one or more bacterium as defined herein.
1 . A method for treating urinary tract infection (UTI) comprising administering gepotidacin or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount in a human in need thereof, wherein the UTI is caused by one or more bacterium selected from:
Staphylococcus saprophyticus; Acinetobacter baumannii, Acinetobacter baumannii anitratus, Acinetobacter pittii, Citrobacter freundii complex, Citrobacter koseri, Haemophilus parainfluenzae, Haemophilus paraphrophilus, Klebsiella oxytoca, Klebsiella variicola, Leclercia adecarboxylata, Proteus hauseri, Proteus peneri, Serratia marcescens, Shigella boydii, Shigella flexneri, Shigella sonnei, Morganella morganii, Providencia rettgeri , drug-resistant Klebsiella pneumoniae , drug-resistant Escherichia coli, Acidovorax temperans, Citrobacter amalonaticus, Providencia stuartii, Pseudomonas putida;
Staphylococcus lugdenensis, Streptococcus agalactiae, Streptococcus group F, Streptococcus group G, Staphylococcus capitis, Staphylococcus caprae, Staphylococcus cohnii, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus simulans, Staphylococcus warneri, Streptococcus anginosus, Streptococcus australis, Streptococcus constellatus, Streptococcus cristatus, Streptococcus gordonii, Streptococcus infantarius, Streptococcus infantis, Streptococcus intermedius, Streptococcus massiliensis, Streptococcus mitts, Streptococcus oralis, Streptococcus mutans, Streptococcus parasanguinis, Streptococcus salivarius, Streptococcus sanguinis, Streptococcus vestibularis;
Bilophila wadsworthia, Sutterella wadsworthensis, Clostridium bifermentans, Clostridium difficile, Eggethella lenta, Peptostreptococcus anaerobius, Peptostreptococcus anaerobius, Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Fusobacterium necrophorum, Fusobacterium nucleatum, Porphyromonas asaccharolytica, Porphyromonas endodontalis, Porphyromonas gingivalis, Porphyromonas levii, Porphyromonas somerae, Prevotella bivia, Prevotella buccae, Prevotella denticola, Prevotella disiens, Prevotella melaninogenica, Veillonella alcalescens dispar, Veillonella parvula, Bifidobacterium adolescentis, Bifidobacterium breve, Bifidobacterium dentium, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Collinsella ( Eubacterium ) aerofaciens, Eubacterium limosum, Eubacterium nodatum, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus iners, Lactobacillus jensenii, Lactobacillus plantarum, and Lactobacillus rhamnosus.
2 . A method according to claim 1 , wherein, prior to the administration of gepotidacin or a pharmaceutically acceptable salt thereof, the UTI is determined to be caused by one or more bacterium named in claim 1 .
3 . A method for treating urinary tract infection (UTI) in a human comprising the following steps:
a) determining whether a sample from a human suspected of having UTI contains one or more bacterium selected from:
Staphylococcus saprophyticus; Acinetobacter baumannii, Acinetobacter baumannii anitratus, Acinetobacter pittii, Citrobacter freundii complex, Citrobacter koseri, Haemophilus parainfluenzae, Haemophilus paraphrophilus, Klebsiella oxytoca, Klebsiella variicola, Leclercia adecarboxylata, Proteus hauseri, Proteus peneri, Serratia marcescens, Shigella boydii, Shigella flexneri, Shigella sonnet, Morganella morganii, Providencia rettgeri , drug-resistant Klebsiella pneumoniae , drug-resistant Escherichia coli, Acidovorax temperans, Citrobacter amalonaticus, Providencia stuartii, Pseudomonas putida;
Staphylococcus lugdenensis, Streptococcus agalactiae, Streptococcus group F, Streptococcus group G, Staphylococcus capitis, Staphylococcus caprae, Staphylococcus cohnii, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus intermedius, Staphylococcus simulans, Staphylococcus warneri, Streptococcus anginosus, Streptococcus australis, Streptococcus constellatus, Streptococcus cristatus, Streptococcus gordonii, Streptococcus infantarius, Streptococcus infantis, Streptococcus intermedius, Streptococcus massiliensis, Streptococcus mitts, Streptococcus oxalis, Streptococcus mutans, Streptococcus parasanguinis, Streptococcus salivarius, Streptococcus sanguinis, Streptococcus vestibularis;
Bilophila wadsworthia, Sutterella wadsworthensis, Clostridium bifermentans, Clostridium difficile, Eggethella lenta, Peptostreptococcus anaerobius, Peptostreptococcus anaerobius, Bacteroides caccae, Bacteroides fragiiis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Fusobacterium necrophorum, Fusobacterium nucleatum, Porphyromonas asaccharolytica, Porphyromonas endodontalis, Porphyromonas gingivalis, Porphyromonas levii, Porphyromonas somerae, Prevotella bivia, Prevotella buccae, Prevotella denticola, Prevotella disiens, Prevotella melaninogenica, Veillonella alcalescens dispar, Veillonella parvula, Bifidobacterium adolescentis, Bifidobacterium breve, Bifidobacterium dentium, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Collinsella ( Eubacterium ) aerofaciens, Eubacterium limosum, Eubacterium nodatum, Lactobacillus acidophilus Lactobacillus crispatus, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus iners, Lactobacillus jensenii, Lactobacillus plantarum , or Lactobacillus rhamnosus;
b) administering gepotidacin or a pharmaceutically acceptable salt thereof in a therapeutically effective amount to the human if one or more of the bacterium is identified in the sample in step (a) and is determined to be the cause of the UTI.
4 . A method as claimed in claim 1 , wherein the UTI is uncomplicated UTI.
5 . A method as claimed in claim 1 , wherein the UTI is recurrent uncomplicated UTI.
6 . A method as claimed in claim 1 , wherein the UTI is complicated UTI.
7 . A method as claimed in claim 1 , wherein the human is female.
8 . A method as claimed in claim 1 , wherein the human is male.
9 . A method as claimed in claim 1 , wherein the human is pregnant, adolescent or paediatric.
10 . A method for treating uncomplicated UTI, comprising administering gepotidacin or a pharmaceutically acceptable salt thereof in a therapeutically effective amount in a human in need thereof, wherein the uncomplicated UTI is caused by one or more bacterium selected from: Staphylococcus saprophyticus , drug-resistant Staphylococcus saprophyticus, Proteus hauseri, Proteus peneri , drug-resistant Klebsiella pneumoniae , and drug-resistant Escherichia coli.
11 . A method as claimed in claim 10 , wherein, prior to the administration of gepotidacin or a pharmaceutically acceptable salt thereof, one or more bacterium selected from Staphylococcus saprophyticus , drug-resistant Staphylococcus saprophyticus, Proteus hauseri, Proteus peneri , drug-resistant Klebsiella pneumoniae , and drug-resistant Escherichia coli is determined to be the cause of the uncomplicated UTI.
12 - 18 . (canceled)
19 . A method as claimed in claim 3 , wherein the UTI is uncomplicated UTI.
20 . A method as claimed in claim 3 , wherein the UTI is recurrent uncomplicated UTI.
21 . A method as claimed in claim 3 , wherein the UTI is complicated UTI.
22 . A method as claimed in claim 3 , wherein the human is female.
23 . A method as claimed in claim 3 , wherein the human is male.
24 . A method as claimed in claim 3 , wherein the human is pregnant, adolescent or paediatric.